The Preclinical Funding Sweetspot: Chase Your Trifecta+
Preclinical Biotech Funding: What Drives Round Size
In The Preclinical Arbitrage, we found a bifurcated market for biotech preclinical companies: most dollars flowing into a small number of huge rounds, and a long tail of companies raising little or nothing at all. We wanted to know why.
So we analyzed all 179 U.S. preclinical biotech financings from January 2024 through mid-2026 and found four dimensions that separate the companies that raise meaningfully from the ones that struggle: CEO experience, lead investor strength, technology origin, and translational stage.
Will go into the details of how we quantify each dimension below, but in an easier funding market, one of these dimensions might have carried a round on its own. Today it takes a trifecta. Companies strong on three of the four raise roughly five times what companies with one or none do. Get all four, and the median round reaches >$150M.
A key finding for us was around valuations: while median round size varies substantially across dimensions, the median valuation stays quite flat across the whole spectrum. A company with zero strong dimensions is priced at a $32.6M median pre-money. A company with all four is priced at $46.0M. Roughly 40% higher, against a staggering 25x difference in median round size.
At Alumni Ventures, we invest in the Trifecta+ region.
Financing Climbs With Every Dimension. Valuation Barely Moves.
Median financing, valuation and share of large rounds by number of funding factors. Companies are grouped by how many strong dimensions they show (0 to 4). Companies past the Trifecta+ threshold (3+ dimensions) raise far larger rounds without a matching jump in valuation.
The Word on the Street
If you’re a biotech CEO looking for funding, the story you hear is that forces outside your control decide how much you can raise. Modality, therapeutic area, the mood of the market. Antibodies and ADCs have commanded far larger rounds between January 2024 and mid-2026 than cell and gene therapy, the categories “nobody wants to touch.”
Median Financing by Modality
Antibody programs raise a median of $86.5M. Gene therapy and gene editing raise $14.0M, roughly a sixth as much.
You can’t decide your modality after the fact, and in most cases you can’t pick your therapeutic area either. Some areas do run hotter. Immunology and inflammation for instance raise far more, on average, than infectious disease.
Median Round Size by Therapeutic Area
Multi-TA and platform companies lead at a $50.0M median, narrowly ahead of immunology and inflammation at $47.5M. Oncology carries the largest total pool of capital, $2.8B, on volume alone.
Combine modality and therapeutic area, and the picture barely changes. Neither factor comes close to explaining why some companies raise $150M and others can’t close $10M.
Median Round Size by Therapeutic Area and Modality
No therapeutic area or modality reliably predicts round size. Medians swing from $2M to $152M with no consistent pattern across rows or columns, so the same modality can raise very large or very small rounds depending on the indication or vice versa.
So we looked past the hand a company is dealt to what founders and management teams actually control.
The Four Dimensions That Matter
1. CEO Experience
We classified every CEO from the 179 financings by their track record at the time of the financing. In cases where companies changed leadership after the round closed, the person who actually raised the money is the one used for the analysis.
Median Round Size by CEO Track Record
Senior pharma executives and repeat founders raise 4 to 6 times what first-time CEOs raise.
2. Lead Investor Strength
Who leads the round matters more than any other single factor we measured. Venture-creation firms (the Flagships, Third Rock, and ARCHs of the world) build companies in-house and fund them at a scale generalist funds rarely match.
Median Round Size by Lead Investor Type
Venture-creation firms lead with an $85.0M median, nearly double a dedicated life-sciences fund and more than 5x a generalist multi-sector VC.
3. Technology Origin
Every company’s core asset is either in-licensed or generated during R&D. Some license it in from another company that already spent years and dollars de-risking it. Some spin it out of a university lab. Some build it themselves from scratch. Those three starting points lead to very different financings.
Where the Asset Came From Changes the Check, Not the Price
Companies that licensed their lead asset from another company raise a $130.0M median round, roughly 4x what companies building in-house raise. Again, we found that valuations land within a few million dollars of $42M regardless of origin.
You can see the flat-valuation trend most clearly right here. When you shift from building the core technoly in-house to in-licensing it from industry, the round size quadruples, but the valuation barely moves. Essentially, investors are paying for the de-risking work that someone else has already finished: and they’re paying for it with larger capital commitments instead of higher prices.
Licensed-In Assets Cluster in the Big Rounds
Two-thirds of licensed-in companies raise over $100M, and none raise under $10M. Among companies building in-house, 45% raise under $25M.
Most assets licensed in came from another biotech. And some came from Asia. The pipeline feeding new preclinical companies runs biotech-to-biotech, and increasingly across the Pacific.
4. Translational Stage
The question here is simple: has the company picked a specific molecule and built a real preclinical data package behind it, or is it still working with a promising lead and a platform?
That line matters more than any milestone further down the path. Companies with a named development candidate raise roughly twice what companies still at the lead stage raise, $32M against $16M. The gap holds no matter who funds them: 1.7x among companies backed by sophisticated investors, 1.5x among companies backed by generalists.
Naming a Development Candidate Roughly Doubles the Round
Companies with a named development candidate raise roughly twice what companies still at the lead-identification stage raise. The gap holds within both investor tiers.
Stack Dimensions until the Sweetspot: It Compounds
Each of the four dimensions matters on its own. What makes this market difficult is that they don’t substitute for one another. Even a world-class CEO can’t make up for a platform lacking a development candidate. A licensed-in asset doesn’t compensate for a thin syndicate. The companies raising real money have several of these working at once.
To test that, we scored all 179 companies from 0 to 3 on each dimension and added them up into a single Funding Stack score, 0 to 12.
Every Point on the Stack Adds Capital
Median round size increases steadily at almost every step, rising from $3.8M at the low end to $188M at the top. While reaching the trifecta threshold is key, adding strength across all four dimensions drives significant gains in capital raised.
The climb is steady and almost exponential. Each additional point on the stack is worth real money, and the effect accelerates: moving from 4 to 5 is worth about $4M, while moving from 7 to 8 is worth about $26M. Number of dimensions and strength within them compounds.
Grouping the scores into four bands shows something the ladder hides. Companies weak across the stack are both rarer and smaller.
Weak Companies Are Both Rarer and Smaller
Companies in the Weak band account for 14% of all rounds, the smallest share of any group, and raise a $6M median. Strong-band companies raise 12x that.
Two things are happening at once here. Weak-stack companies raise less, which is the finding we set out to test. They also show up less often, making up the smallest slice of the market. And this dataset only counts companies that closed a round at all, so we don’t include all the hundreds of companies that were trying to fundraise and were not successful.
The takeaway is simple: you don’t need a perfect score. Hitting three of the four markers puts you in the range for a successful, large round, which is a realistic goal for most companies. What doesn’t work is relying on one strength to carry the rest.
Case Studies: The Trifecta in Practice
Kanvas Bio (3 out of 4 dimensions)
MICROBIOME – SPATIAL AI
- Home
What it does
Uses spatial imaging and AI to map which gut microbes are active and how they interact with immune cells, then makes defined microbial drugs that help cancer immunotherapy work better and with fewer side effects. - Home
Traction
FDA has cleared INDs for two programs: KAN-001, which boosts checkpoint inhibitors in lung cancer, and KAN-004, for checkpoint inhibitor–induced colitis. Kanvas closed a $48.0M Series A in May 2026. - Home
Co-investors
Led by DCVC with Gates Ventures participating. George Church sits on the scientific advisory board.
RegCell (3 out of 4 dimensions)
CELL THERAPY – AUTOIMMUNE DISEASE
- Home
What it does
Develops regulatory T-cell therapies for autoimmune disease, built on the Nobel Prize-winning science of founder Shimon Sakaguchi, who discovered Tregs. - Home
Traction
CEO Michael McCullar previously served as COO of Tolero Pharmaceuticals through its $780M sale to Sumitomo Dainippon, and as SVP of Business Development at Astex Pharmaceuticals through its acquisition by Otsuka. RegCell closed a $40.0M Series A, entering Phase 1b/2a in Q4 2026. - Home
Co-investors
Led by Playground Global
Portfolio companies are shown for illustrative purposes only; not necessarily indicative of any AV fund or investor. Investments shown are not available to future investors, except potentially in the case of follow-on investments. Past performance does not guarantee future results.
What This Means If You’re Building a Company
Spinning out of academia
Think like a drug developer. Before you start raising, focus on establishing a clear development candidate with a solid data package behind it. This is the one lever in our analysis that pays off regardless of who ends up funding you: the step-up holds whether your round is led by a top-tier life-science fund or a generalist. Use your grant money and your early capital to advance the molecule rather than to publish another paper.
Plan from day one to hand the CEO seat to an experienced operator. Only 17% of academic-origin companies in this dataset kept the founder in that role. That’s close to the default path in this market, and founders who plan for it tend to navigate it better than founders who get talked into it later.
One number worth knowing before you start: academic-origin companies raise a $44.0M median round, well ahead of companies building their technology from scratch, and behind only companies that licensed a de-risked asset from another biotech. A university lab is a strong starting point in this market.
Already running a company
- Home
Find an experienced CEO to partner with.
Experienced executives and repeat founders raise 2 to 6 times what first-time CEOs raise, and leadership is the one dimension a company can change directly. Raising more dilutes founders, but especially in biotech this is balanced with option pools so that founders still target upside at exit. - Home
Seek incubation from a venture-creation fund.
These firms lead rounds at an $85.0M median, nearly double a dedicated life-sciences fund. They have the network, experience and capital to support your company. - Home
Get outside validation on the asset.
A pharma partnership, a strategic investment, or a license from a company that has already done real work on the molecule all signal the same thing to investors: somebody credible has looked at this closely and put something behind it. - Home
Seriously consider licensing in a later-stage technology.
The strongest single signal we found. Companies that licensed their core asset from another biotech raised a $130.0M median round, roughly 4x what companies building in-house raised, at essentially the same valuation. The assets are out there, and they don't all come from big pharma. Most of these deals were biotech-to-biotech, and several came out of Asia.
You Can Back the Next Generation of Biotech Breakthroughs With Us
For investors, the biggest finding is that companies strong across three or four of the dimensions analyzed raised up to 25 times more capital, yet commanded similar median pre-money valuations than companies with fewer dimensions. In other words, the companies best positioned to attract significant financing weren’t necessarily much more expensive to invest in.
Of course, raising more money doesn’t guarantee a successful drug. But biotech development is expensive and science brings setbacks before breakthroughs. Having experienced leadership, strong financial backing, and a credible path to the clinic can make all the difference between promising science that stalls and a medicine that gets a real shot at helping patients.
At Alumni Ventures, we chase companies that are strong in multiple dimensions. We invest alongside leading biotech investors, looking for companies that bring together strong science, experienced teams, and the resources to move through critical development milestones. We believe there’s a compelling opportunity to back these companies early, before much of their potential value has been realized, and you can invest with us.
Because ultimately, the breakthroughs that matter aren’t just the ones discovered in the lab. They’re the ones that make it to patients.
Data sources and methodology. The study universe was built from Silverwood Partners’ weekly healthcare financing review (102 issues, January 2024 to February 2026; 1,815 financing entries screened), which is compiled from PitchBook data. Each of the 179 included financings was then verified company by company against PitchBook company and deal records (business status at financing, round number, headquarters, amount and date). Supplementary fields were sourced as follows:
- Preclinical status at financing: ClinicalTrials.gov registrations and first-dosing dates, company press releases, and trade press coverage (Fierce Biotech, Endpoints News, BioSpace). A company was excluded if any human dosing of its lead asset occurred before the financing date.
- CEO background: LinkedIn, company leadership pages, press releases and conference speaker biographies, with each CEO’s career history verified as of the financing date rather than today.
- Asset and IP origin: company websites, university technology-transfer announcements and licensing press releases.
- Lead investors and syndicate: PitchBook deal records, company financing announcements and investor press releases.
- Pharma partnerships before the financing: company and partner press releases.
- Valuations: PitchBook-disclosed pre- and post-money valuations (84 of 179 rounds). Third-party secondary-market estimates (Forge, Tracxn, Dealroom) were reviewed but not used as financing valuations.
- Round amounts: reconciled against SEC Form D filings where announced and recorded figures conflicted.
This communication is from Alumni Ventures, a for-profit venture capital company that is not affiliated with or endorsed by any school. It is not personalized advice, and AV only provides advice to its client funds. This communication is neither an offer to sell, nor a solicitation of an offer to purchase, any security. Such offers are made only pursuant to the formal offering documents for the fund(s) concerned, and describe significant risks and other material information that should be carefully considered before investing. For additional information, please see here. Achievement of investment objectives, including any amount of investment return, cannot be guaranteed. Co-investors are shown for illustrative purposes only, do not reflect all organizations with which AV co-invests, and do not necessarily indicate future co-investors. Example portfolio companies shown are not available to future investors, except potentially in the case of follow-on investments. Venture capital investing involves substantial risk, including risk of loss of all capital invested. Diversification cannot prevent investment loss; it is a strategy to mitigate investment risk. This communication includes forward-looking statements, generally consisting of any statement pertaining to any issue other than historical fact, including without limitation predictions, financial projections, the anticipated results of the execution of any plan or strategy, the expectation or belief of the speaker, or other events or circumstances to exist in the future. Forward-looking statements are not representations of actual fact, depend on certain assumptions that may not be realized, and are not guaranteed to occur. Any forward-looking statements included in this communication speak only as of the date of the communication. AV and its affiliates disclaim any obligation to update, amend, or alter such forward-looking statements, whether due to subsequent events, new information, or otherwise.